Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 48

1.

Amyloid-β, Tau, and 18F-Fluorodeoxyglucose Positron Emission Tomography in Posttraumatic Stress Disorder.

Elias A, Cummins T, Lamb F, Tyrrell R, Dore V, Williams R, Rosenfeld JV, Hopwood M, Villemagne VL, Rowe CC.

J Alzheimers Dis. 2019 Nov 18. doi: 10.3233/JAD-190913. [Epub ahead of print]

PMID:
31771068
2.

Using subjective cognitive decline to identify high global amyloid in community-based samples: A cross-cohort study.

Buckley RF, Sikkes S, Villemagne VL, Mormino EC, Rabin JS, Burnham S, Papp KV, Doré V, Masters CL, Properzi MJ, Schultz AP, Johnson KA, Rentz DM, Sperling RA, Amariglio RE.

Alzheimers Dement (Amst). 2019 Sep 25;11:670-678. doi: 10.1016/j.dadm.2019.08.004. eCollection 2019 Dec.

3.

Comparison of oral, intravenous, and subcutaneous fluid therapy for resuscitation of calves with diarrhea.

Doré V, Foster DM, Ru H, Smith GW.

J Dairy Sci. 2019 Dec;102(12):11337-11348. doi: 10.3168/jds.2019-16970. Epub 2019 Oct 9.

PMID:
31606222
4.

The dawn of robust individualised risk models for dementia.

Burnham SC, Loi SM, Doecke J, Fedyashov V, Dore V, Villemagne VL, Masters CL.

Lancet Neurol. 2019 Nov;18(11):985-987. doi: 10.1016/S1474-4422(19)30353-9. Epub 2019 Sep 13. No abstract available.

PMID:
31526626
5.

The trinity of tau, trauma, and time.

Villemagne VL, Doré V, Burnham S.

Lancet Neurol. 2019 Aug;18(8):715-717. doi: 10.1016/S1474-4422(19)30219-4. Epub 2019 Jun 11. No abstract available.

PMID:
31201004
6.

Increased cerebral blood flow with increased amyloid burden in the preclinical phase of alzheimer's disease.

Fazlollahi A, Calamante F, Liang X, Bourgeat P, Raniga P, Dore V, Fripp J, Ames D, Masters CL, Rowe CC, Connelly A, Villemagne VL, Salvado O; Australian Imaging Biomarkers and Lifestyle (AIBL) Research Group.

J Magn Reson Imaging. 2019 May 30. doi: 10.1002/jmri.26810. [Epub ahead of print]

PMID:
31145515
7.

Comparison of 18F-florbetaben quantification results using the standard Centiloid, MR-based, and MR-less CapAIBL® approaches: Validation against histopathology.

Doré V, Bullich S, Rowe CC, Bourgeat P, Konate S, Sabri O, Stephens AW, Barthel H, Fripp J, Masters CL, Dinkelborg L, Salvado O, Villemagne VL, De Santi S.

Alzheimers Dement. 2019 Jun;15(6):807-816. doi: 10.1016/j.jalz.2019.02.005. Epub 2019 May 14.

PMID:
31101517
8.

Imaging of tau deposits in adults with Niemann-Pick type C disease: a case-control study.

Villemagne VL, Velakoulis D, Doré V, Bozinoski S, Masters CL, Rowe CC, Walterfang M.

Eur J Nucl Med Mol Imaging. 2019 May;46(5):1132-1138. doi: 10.1007/s00259-019-4273-7. Epub 2019 Jan 28.

PMID:
30690666
9.

Centiloid scaling for quantification of brain amyloid with [18F]flutemetamol using multiple processing methods.

Battle MR, Pillay LC, Lowe VJ, Knopman D, Kemp B, Rowe CC, Doré V, Villemagne VL, Buckley CJ.

EJNMMI Res. 2018 Dec 5;8(1):107. doi: 10.1186/s13550-018-0456-7.

10.

Diagnostic accuracy of imaging brain vesicular monoamine transporter type 2 (VMAT2) in clinically uncertain parkinsonian syndrome (CUPS): a 3-year follow-up study in community patients.

Xu SS, Alexander PK, Lie Y, Dore V, Bozinovski S, Mulligan RS, Young K, Villemagne VL, Rowe CC.

BMJ Open. 2018 Nov 15;8(11):e025533. doi: 10.1136/bmjopen-2018-025533.

11.

Multisite study of the relationships between antemortem [11C]PIB-PET Centiloid values and postmortem measures of Alzheimer's disease neuropathology.

La Joie R, Ayakta N, Seeley WW, Borys E, Boxer AL, DeCarli C, Doré V, Grinberg LT, Huang E, Hwang JH, Ikonomovic MD, Jack C Jr, Jagust WJ, Jin LW, Klunk WE, Kofler J, Lesman-Segev OH, Lockhart SN, Lowe VJ, Masters CL, Mathis CA, McLean CL, Miller BL, Mungas D, O'Neil JP, Olichney JM, Parisi JE, Petersen RC, Rosen HJ, Rowe CC, Spina S, Vemuri P, Villemagne VL, Murray ME, Rabinovici GD.

Alzheimers Dement. 2019 Feb;15(2):205-216. doi: 10.1016/j.jalz.2018.09.001. Epub 2018 Oct 19.

PMID:
30347188
12.

Risk of Alzheimer's Disease in Obstructive Sleep Apnea Syndrome: Amyloid-β and Tau Imaging.

Elias A, Cummins T, Tyrrell R, Lamb F, Dore V, Williams R, Rosenfeld JV, Hopwood M, Villemagne VL, Rowe CC.

J Alzheimers Dis. 2018;66(2):733-741. doi: 10.3233/JAD-180640.

PMID:
30320587
13.

Implementing the centiloid transformation for 11C-PiB and β-amyloid 18F-PET tracers using CapAIBL.

Bourgeat P, Doré V, Fripp J, Ames D, Masters CL, Salvado O, Villemagne VL, Rowe CC; AIBL research group.

Neuroimage. 2018 Dec;183:387-393. doi: 10.1016/j.neuroimage.2018.08.044. Epub 2018 Aug 18.

PMID:
30130643
14.

Author Correction: Imaging tau and amyloid-β proteinopathies in Alzheimer disease and other conditions.

Villemagne VL, Doré V, Burnham SC, Masters CL, Rowe CC.

Nat Rev Neurol. 2018 Jul;14(7):446. doi: 10.1038/s41582-018-0021-z.

PMID:
29880829
15.

Sex, amyloid, and APOE ε4 and risk of cognitive decline in preclinical Alzheimer's disease: Findings from three well-characterized cohorts.

Buckley RF, Mormino EC, Amariglio RE, Properzi MJ, Rabin JS, Lim YY, Papp KV, Jacobs HIL, Burnham S, Hanseeuw BJ, Doré V, Dobson A, Masters CL, Waller M, Rowe CC, Maruff P, Donohue MC, Rentz DM, Kirn D, Hedden T, Chhatwal J, Schultz AP, Johnson KA, Villemagne VL, Sperling RA; Alzheimer's Disease Neuroimaging Initiative; Australian Imaging, Biomarker and Lifestyle study of ageing; Harvard Aging Brain Study.

Alzheimers Dement. 2018 Sep;14(9):1193-1203. doi: 10.1016/j.jalz.2018.04.010. Epub 2018 May 24.

16.

Self-Reported Physical Activity is Associated with Tau Burden Measured by Positron Emission Tomography.

Brown BM, Rainey-Smith SR, Dore V, Peiffer JJ, Burnham SC, Laws SM, Taddei K, Ames D, Masters CL, Rowe CC, Martins RN, Villemagne VL.

J Alzheimers Dis. 2018;63(4):1299-1305. doi: 10.3233/JAD-170998.

PMID:
29758940
17.

Imaging tau and amyloid-β proteinopathies in Alzheimer disease and other conditions.

Villemagne VL, Doré V, Burnham SC, Masters CL, Rowe CC.

Nat Rev Neurol. 2018 Apr;14(4):225-236. doi: 10.1038/nrneurol.2018.9. Epub 2018 Feb 16. Review. Erratum in: Nat Rev Neurol. 2018 Jul;14(7):446.

PMID:
29449700
18.

High performance plasma amyloid-β biomarkers for Alzheimer's disease.

Nakamura A, Kaneko N, Villemagne VL, Kato T, Doecke J, Doré V, Fowler C, Li QX, Martins R, Rowe C, Tomita T, Matsuzaki K, Ishii K, Ishii K, Arahata Y, Iwamoto S, Ito K, Tanaka K, Masters CL, Yanagisawa K.

Nature. 2018 Feb 8;554(7691):249-254. doi: 10.1038/nature25456. Epub 2018 Jan 31.

PMID:
29420472
19.

Thirty Years of Research on Gay Men and HIV Prevention in France: A Narrative Review of the Literature.

Girard G, Doré V.

Arch Sex Behav. 2018 Jul;47(5):1341-1349. doi: 10.1007/s10508-018-1163-1. Epub 2018 Feb 7. Review.

PMID:
29417262
20.

KIBRA is associated with accelerated cognitive decline and hippocampal atrophy in APOE ε4-positive cognitively normal adults with high Aβ-amyloid burden.

Porter T, Burnham SC, Doré V, Savage G, Bourgeat P, Begemann K, Milicic L, Ames D, Bush AI, Maruff P, Masters CL, Rowe CC, Rainey-Smith S, Martins RN, Groth D, Verdile G, Villemagne VL, Laws SM.

Sci Rep. 2018 Feb 1;8(1):2034. doi: 10.1038/s41598-018-20513-y.

21.

Post-exposure prophylaxis with doxycycline to prevent sexually transmitted infections in men who have sex with men: an open-label randomised substudy of the ANRS IPERGAY trial.

Molina JM, Charreau I, Chidiac C, Pialoux G, Cua E, Delaugerre C, Capitant C, Rojas-Castro D, Fonsart J, Bercot B, Bébéar C, Cotte L, Robineau O, Raffi F, Charbonneau P, Aslan A, Chas J, Niedbalski L, Spire B, Sagaon-Teyssier L, Carette D, Mestre SL, Doré V, Meyer L; ANRS IPERGAY Study Group.

Lancet Infect Dis. 2018 Mar;18(3):308-317. doi: 10.1016/S1473-3099(17)30725-9. Epub 2017 Dec 8.

PMID:
29229440
22.

Insulin resistance is associated with reductions in specific cognitive domains and increases in CSF tau in cognitively normal adults.

Laws SM, Gaskin S, Woodfield A, Srikanth V, Bruce D, Fraser PE, Porter T, Newsholme P, Wijesekara N, Burnham S, Doré V, Li QX, Maruff P, Masters CL, Rainey-Smith S, Rowe CC, Salvado O, Villemagne VL, Martins RN, Verdile G.

Sci Rep. 2017 Aug 29;7(1):9766. doi: 10.1038/s41598-017-09577-4.

23.

Amyloid β-associated cognitive decline in the absence of clinical disease progression and systemic illness.

Harrington KD, Lim YY, Ames D, Hassenstab J, Laws SM, Martins RN, Rainey-Smith S, Robertson J, Rowe CC, Salvado O, Doré V, Villemagne VL, Snyder PJ, Masters CL, Maruff P.

Alzheimers Dement (Amst). 2017 Jun 9;8:156-164. doi: 10.1016/j.dadm.2017.05.006. eCollection 2017.

24.

Efficacy, safety, and effect on sexual behaviour of on-demand pre-exposure prophylaxis for HIV in men who have sex with men: an observational cohort study.

Molina JM, Charreau I, Spire B, Cotte L, Chas J, Capitant C, Tremblay C, Rojas-Castro D, Cua E, Pasquet A, Bernaud C, Pintado C, Delaugerre C, Sagaon-Teyssier L, Mestre SL, Chidiac C, Pialoux G, Ponscarme D, Fonsart J, Thompson D, Wainberg MA, Doré V, Meyer L; ANRS IPERGAY Study Group.

Lancet HIV. 2017 Sep;4(9):e402-e410. doi: 10.1016/S2352-3018(17)30089-9. Epub 2017 Jul 23.

PMID:
28747274
25.

Trajectories of depressive and anxiety symptoms in older adults: a 6-year prospective cohort study.

Holmes SE, Esterlis I, Mazure CM, Lim YY, Ames D, Rainey-Smith S, Fowler C, Ellis K, Martins RN, Salvado O, Doré V, Villemagne VL, Rowe CC, Laws SM, Masters CL, Pietrzak RH, Maruff P; Australian Imaging, Biomarkers and Lifestyle Research Group.

Int J Geriatr Psychiatry. 2018 Feb;33(2):405-413. doi: 10.1002/gps.4761. Epub 2017 Jul 24.

26.

Partial volume model for brain MRI scan using MP2RAGE.

Duché Q, Saint-Jalmes H, Acosta O, Raniga P, Bourgeat P, Doré V, Egan GF, Salvado O.

Hum Brain Mapp. 2017 Oct;38(10):5115-5127. doi: 10.1002/hbm.23719. Epub 2017 Jul 5.

PMID:
28677254
27.

18F-Florbetaben PET beta-amyloid binding expressed in Centiloids.

Rowe CC, Doré V, Jones G, Baxendale D, Mulligan RS, Bullich S, Stephens AW, De Santi S, Masters CL, Dinkelborg L, Villemagne VL.

Eur J Nucl Med Mol Imaging. 2017 Nov;44(12):2053-2059. doi: 10.1007/s00259-017-3749-6. Epub 2017 Jun 22.

28.

Assessment of ocular discomfort caused by 5 shampoos using the Slug Mucosal Irritation test.

Petit JY, Doré V, Marignac G, Perrot S.

Toxicol In Vitro. 2017 Apr;40:243-247. doi: 10.1016/j.tiv.2017.01.002. Epub 2017 Jan 4.

PMID:
28063820
29.

Aβ-amyloid and Tau Imaging in Dementia.

Villemagne VL, Doré V, Bourgeat P, Burnham SC, Laws S, Salvado O, Masters CL, Rowe CC.

Semin Nucl Med. 2017 Jan;47(1):75-88. doi: 10.1053/j.semnuclmed.2016.09.006. Epub 2016 Oct 13. Review.

PMID:
27987560
30.

Cerebral Disorders of Calves.

Dore V, Smith G.

Vet Clin North Am Food Anim Pract. 2017 Mar;33(1):27-41. doi: 10.1016/j.cvfa.2016.09.004. Epub 2016 Dec 8. Review.

PMID:
27939221
31.

β-Amyloid, APOE and BDNF Genotype, and Depressive and Anxiety Symptoms in Cognitively Normal Older Women and Men.

Holmes SE, Esterlis I, Mazure CM, Lim YY, Ames D, Rainey-Smith S, Martins RN, Salvado O, Dore V, Villemagne VL, Rowe CC, Laws SM, Masters CL, Maruff P, Pietrzak RH; Australian Imaging, Biomarkers, Lifestyle Research Group.

Am J Geriatr Psychiatry. 2016 Dec;24(12):1191-1195. doi: 10.1016/j.jagp.2016.08.007. Epub 2016 Aug 17.

PMID:
27742526
32.

Clinical and cognitive trajectories in cognitively healthy elderly individuals with suspected non-Alzheimer's disease pathophysiology (SNAP) or Alzheimer's disease pathology: a longitudinal study.

Burnham SC, Bourgeat P, Doré V, Savage G, Brown B, Laws S, Maruff P, Salvado O, Ames D, Martins RN, Masters CL, Rowe CC, Villemagne VL; AIBL Research Group.

Lancet Neurol. 2016 Sep;15(10):1044-53. doi: 10.1016/S1474-4422(16)30125-9. Epub 2016 Jul 20.

PMID:
27450471
33.

Atrophy, hypometabolism and clinical trajectories in patients with amyloid-negative Alzheimer's disease.

Chételat G, Ossenkoppele R, Villemagne VL, Perrotin A, Landeau B, Mézenge F, Jagust WJ, Dore V, Miller BL, Egret S, Seeley WW, van der Flier WM, La Joie R, Ames D, van Berckel BN, Scheltens P, Barkhof F, Rowe CC, Masters CL, de La Sayette V, Bouwman F, Rabinovici GD.

Brain. 2016 Sep;139(Pt 9):2528-39. doi: 10.1093/brain/aww159. Epub 2016 Jun 29.

34.

Heritability and genetic correlation between the cerebral cortex and associated white matter connections.

Shen KK, Doré V, Rose S, Fripp J, McMahon KL, de Zubicaray GI, Martin NG, Thompson PM, Wright MJ, Salvado O.

Hum Brain Mapp. 2016 Jun;37(6):2331-47. doi: 10.1002/hbm.23177. Epub 2016 Mar 23.

35.

Standardized Expression of 18F-NAV4694 and 11C-PiB β-Amyloid PET Results with the Centiloid Scale.

Rowe CC, Jones G, Doré V, Pejoska S, Margison L, Mulligan RS, Chan JG, Young K, Villemagne VL.

J Nucl Med. 2016 Aug;57(8):1233-7. doi: 10.2967/jnumed.115.171595. Epub 2016 Feb 16.

36.

Efficacy of guar gum-based ronidazole capsules as a treatment for Tritrichomonas foetus infection in cats.

Grellet A, Makhlouf SE, Desquilbet L, Hovhannessian F, Boogaerts C, Dore V, Anthony M, Espana B, Prouillac C, Kirilov P, Polack B, Perrot S.

J Feline Med Surg. 2017 Feb;19(2):177-184. doi: 10.1177/1098612X15621353. Epub 2016 Jul 10.

PMID:
26662037
37.

Subjective Memory Complaints in APOEɛ4 Carriers are Associated with High Amyloid-β Burden.

Zwan MD, Villemagne VL, Doré V, Buckley R, Bourgeat P, Veljanoski R, Salvado O, Williams R, Margison L, Rembach A, Macaulay SL, Martins R, Ames D, van der Flier WM, Ellis KA, Scheltens P, Masters CL, Rowe CC.

J Alzheimers Dis. 2016;49(4):1115-22. doi: 10.3233/JAD-150446.

PMID:
26639956
38.

On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection.

Molina JM, Capitant C, Spire B, Pialoux G, Cotte L, Charreau I, Tremblay C, Le Gall JM, Cua E, Pasquet A, Raffi F, Pintado C, Chidiac C, Chas J, Charbonneau P, Delaugerre C, Suzan-Monti M, Loze B, Fonsart J, Peytavin G, Cheret A, Timsit J, Girard G, Lorente N, Préau M, Rooney JF, Wainberg MA, Thompson D, Rozenbaum W, Doré V, Marchand L, Simon MC, Etien N, Aboulker JP, Meyer L, Delfraissy JF; ANRS IPERGAY Study Group.

N Engl J Med. 2015 Dec 3;373(23):2237-46. doi: 10.1056/NEJMoa1506273. Epub 2015 Dec 1.

39.

Definition of prepartum hyperketonemia in dairy goats.

Doré V, Dubuc J, Bélanger AM, Buczinski S.

J Dairy Sci. 2015 Jul;98(7):4535-43. doi: 10.3168/jds.2014-9172. Epub 2015 Apr 29.

40.

Comparison of MR-less PiB SUVR quantification methods.

Bourgeat P, Villemagne VL, Dore V, Brown B, Macaulay SL, Martins R, Masters CL, Ames D, Ellis K, Rowe CC, Salvado O, Fripp J; AIBL Research Group.

Neurobiol Aging. 2015 Jan;36 Suppl 1:S159-66. doi: 10.1016/j.neurobiolaging.2014.04.033. Epub 2014 Aug 27.

PMID:
25257985
41.

In vivo evaluation of a novel tau imaging tracer for Alzheimer's disease.

Villemagne VL, Furumoto S, Fodero-Tavoletti MT, Mulligan RS, Hodges J, Harada R, Yates P, Piguet O, Pejoska S, Doré V, Yanai K, Masters CL, Kudo Y, Rowe CC, Okamura N.

Eur J Nucl Med Mol Imaging. 2014 May;41(5):816-26. doi: 10.1007/s00259-013-2681-7. Epub 2014 Feb 11.

PMID:
24514874
42.

MR-less surface-based amyloid assessment based on 11C PiB PET.

Zhou L, Salvado O, Dore V, Bourgeat P, Raniga P, Macaulay SL, Ames D, Masters CL, Ellis KA, Villemagne VL, Rowe CC, Fripp J; AIBL Research Group.

PLoS One. 2014 Jan 10;9(1):e84777. doi: 10.1371/journal.pone.0084777. eCollection 2014.

43.

Silica nanoparticles for micro-particle imaging velocimetry: fluorosurfactant improves nanoparticle stability and brightness of immobilized iridium(III) complexes.

Lewis DJ, Dore V, Rogers NJ, Mole TK, Nash GB, Angeli P, Pikramenou Z.

Langmuir. 2013 Nov 26;29(47):14701-8. doi: 10.1021/la403172m. Epub 2013 Nov 13.

PMID:
24164285
44.

MilxXplore: a web-based system to explore large imaging datasets.

Bourgeat P, Dore V, Villemagne VL, Rowe CC, Salvado O, Fripp J.

J Am Med Inform Assoc. 2013 Nov-Dec;20(6):1046-52. doi: 10.1136/amiajnl-2012-001545. Epub 2013 Jun 17.

45.

Cross-sectional and longitudinal analysis of the relationship between Aβ deposition, cortical thickness, and memory in cognitively unimpaired individuals and in Alzheimer disease.

Doré V, Villemagne VL, Bourgeat P, Fripp J, Acosta O, Chetélat G, Zhou L, Martins R, Ellis KA, Masters CL, Ames D, Salvado O, Rowe CC.

JAMA Neurol. 2013 Jul;70(7):903-11. doi: 10.1001/jamaneurol.2013.1062.

PMID:
23712469
46.

Short communication: evaluation of the accuracy of an electronic on-farm test to quantify blood β-hydroxybutyrate concentration in dairy goats.

Doré V, Dubuc J, Bélanger AM, Buczinski S.

J Dairy Sci. 2013 Jul;96(7):4505-7. doi: 10.3168/jds.2012-6321. Epub 2013 Apr 28.

47.

MR-less surface-based amyloid estimation by subject-specific atlas selection and Bayesian fusion.

Zhou L, Salvado O, Dore V, Bourgeat P, Raniga P, Villemagne VL, Rowe CC, Fripp J; AIBL Research Group.

Med Image Comput Comput Assist Interv. 2012;15(Pt 2):220-7.

PMID:
23286052
48.

Cortical surface mapping using topology correction, partial flattening and 3D shape context-based non-rigid registration for use in quantifying atrophy in Alzheimer's disease.

Acosta O, Fripp J, Doré V, Bourgeat P, Favreau JM, Chételat G, Rueda A, Villemagne VL, Szoeke C, Ames D, Ellis KA, Martins RN, Masters CL, Rowe CC, Bonner E, Gris F, Xiao D, Raniga P, Barra V, Salvado O.

J Neurosci Methods. 2012 Mar 30;205(1):96-109. doi: 10.1016/j.jneumeth.2011.12.011. Epub 2011 Dec 29.

Supplemental Content

Support Center